Efficacy and safety of regdanvimab in patients with mild to moderate COVID-19: A rapid review and meta-analysis.

Published in: British journal of clinical pharmacology (2023)

Regdanvimab was not effective in reducing mortality and hospital admission rate in patients with mild to moderate COVID-19, but it was effective in improving other efficacy outcomes. Further research is needed to confirm these findings.

Keyphrases

coronavirus disease
sars cov
emergency department
healthcare
respiratory syndrome coronavirus
cardiovascular events
risk factors
type diabetes
acute care
adipose tissue
insulin resistance
quantum dots
sensitive detection
glycemic control